 | Up a level |
Boysen, Gunther; Rodrigues, Daniel N; Rescigno, Pasquale; Seed, George; Dolling, David; Riisnaes, Ruth; Crespo, Mateus; Zafeiriou, Zafeiris; Sumanasuriya, Semini; Bianchini, Diletta; Hunt, Joanne; Moloney, Deirdre; Perez-Lopez, Raquel; Tunariu, Nina; Miranda, Susana; Figueiredo, Inês; Ferreira, Ana; Christova, Rossitza; Gil, Veronica; Aziz, Sara; ... (2018). SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity. Clinical cancer research, 24(22), pp. 5585-5593. American Association for Cancer Research 10.1158/1078-0432.CCR-18-0937
Dai, Xiangpeng; Gan, Wenjian; Li, Xiaoning; Wang, Shangqian; Zhang, Wei; Huang, Ling; Liu, Shengwu; Zhong, Qing; Guo, Jianping; Zhang, Jinfang; Chen, Ting; Shimizu, Kouhei; Beca, Francisco; Blattner, Mirjam; Vasudevan, Divya; Buckley, Dennis L; Qi, Jun; Buser, Lorenz; Liu, Pengda; Inuzuka, Hiroyuki; ... (2017). Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nature medicine, 23(9), pp. 1063-1071. Nature Publishing Group 10.1038/nm.4378
